Tubastatin A (Hydrochloride)

Tubastatin A (Hydrochloride)

• Product Name Alternative: Tubastatin A HCl; TSA HCl
• CAS Number: 1310693-92-5
• UNSPSC Description: Tubastatin A Hydrochloride (Tubastatin A HCl) is a potent and selective?HDAC6?inhibitor with?IC50?of 15 nM in a cell-free assay, and is selective (1000-fold more) against all other isozymes except HDAC8 (57-fold more). Tubastatin A Hydrochloride also inhibits HDAC10 and metallo-β-lactamase domain-containing protein?2 (MBLAC2).
• Target Antigen: Apoptosis; Autophagy; Beta-lactamase; HDAC
• Type: Reference compound
• Related Pathways: Anti-infection;Apoptosis;Autophagy;Cell Cycle/DNA Damage;Epigenetics
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/Tubastatin-A-Hydrochloride.html
• Purity: 98.19
• Solubility: DMSO : 10.8 mg/mL (ultrasonic;warming)|H2O : 6.67 mg/mL (ultrasonic)
• Smiles: O=C(C1=CC=C(C=C1)CN2C3=C(C4=C2C=CC=C4)CN(C)CC3)NO.[H]Cl
• Molecular Weight: 371.86
• References & Citations: [1]Kyle V. Butler et al. Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A J. Am. Chem. Soc., 2010, 132 (31), pp 10842-10846|[2]de Zoeten EF, et al. Histone deacetylase 6 and heat shock protein 90 control the functions of Foxp3(+) T-regulatory cells. Mol Cell Biol. 2011 May;31(10):2066-78.|[3]Di Fulvio S, et al. Dysferlin interacts with histone deacetylase 6 and increases alpha-tubulin acetylation. PLoS One. 2011;6(12):e28563|[4]Ketene AN, et al. Actin filaments play a primary role for structural integrity and viscoelastic response in cells. Integr Biol (Camb). 2012 May;4(5):540-9.|[5]Brijmohan AS, et al. HDAC6 Inhibition Promotes Transcription Factor EB Activation and Is Protective in Experimental Kidney Disease. Front Pharmacol. 2018 Feb 1;9:34.|[6]Severin Lechner, et al. Target deconvolution of HDAC pharmacopoeia reveals MBLAC2 as common off-target. Nat Chem Biol. 2022 Apr 28. Atherosclerosis. 2021 Jan;317:1-9.|Cell Death Dis. 2022 Oct 21;13(10):888.|Front Pharmacol. 2018 Feb 1;9:34.|Hum Mol Genet. 2022 Jan 12;ddac008.|Neurotherapeutics. 2023 Jun 2.|PLoS Pathog. 2021 Sep 20;17(9):e1009940.|Acta Pharm Sin B. 20 May 2022.|Aging. 2021 Mar 19;13(7):9820-9837.|Am J Pathol. 2020 Dec;190(12):2376-2386.|Antioxidants (Basel). 2022 Apr 7;11(4):732.|Antioxidants. 2020 Jul 9;9(7):599.|Biochim Biophys Acta Mol Cell Res. 2020 May;1867(5):118676.|bioRxiv. 2021 Feb 25.|BMC Biol. 2018 Oct 18;16(1):116.|J Dermatol Sci. 2022 May 17;S0923-1811(22)00125-6.|J Med Chem. 2023 Nov 16.|J Med Chem. 2024 Aug 15.|J Mol Neurosci. 2024 Mar 13.|J Nutr. 2020 Jul 1;150(7):1790-1798.|Medical Science, University of Toronto. 2017 Nov.|Mol Cancer Res. 2014 May;12(5):681-93.|Mol Cancer Res. 2022 Mar 4;molcanres.0923.2021.|Neurotherapeutics. 2023 Jun 2.|NPJ Precis Oncol. 2024 Mar 7;8(1):66.|Patent. US20180263995A1.
• Shipping Conditions: Room Temperature
• Storage Conditions: 4°C (Powder, sealed storage, away from moisture)
• Clinical Information: No Development Reported